| Literature DB >> 34694330 |
Elly Mertens1, Els Genbrugge1, Junior Ocira1, José L Peñalvo1.
Abstract
Food policies for the prevention and management of diet-related non-communicable diseases (NCDs) have been increasingly relying on microsimulation models (MSMs) to assess effectiveness. Given the increased uptake of MSMs, this review aims to provide an overview of the characteristics of MSMs that link diets with NCDs. A comprehensive review was conducted in PubMed and Web of Knowledge. Inclusion criteria were: (i) findings from a MSM, (ii) diets, foods or nutrients as main exposure of interest, (iii) NCDs, such as overweight/obesity, type 2 diabetes, coronary heart disease, stroke or cancer as disease outcome for impact assessment. This review included information from 33 studies using MSM in analyzing diet and diverse food policies on NCDs. Hereby, most models employed stochastic, discrete-time, dynamic microsimulation techniques to calculate anticipated (cost-)effectiveness of strategies based on food pricing, food reformulation or dietary (lifestyle) interventions. Currently available models differ in the methodology used for quantifying the effect of the dietary changes on disease, and in the method for modelling disease incidence and mortality. However, all studies provided evidence that the models were sufficiently capturing the close-to-reality situation by justifying their choice of model parameters and validating externally their modelled disease incidence and mortality with observed or predicted event data. With the increasing use of various MSMs, between-model comparisons, facilitated by open access models and good reporting practices, would be important for judging model's accuracy, leading to continued improvement in the methodologies for developing and applying MSMs, and subsequently a better understanding of the results by policymakers. A STATEMENT OF SIGNIFICANCE: Given the advancement in the application of microsimulation modelling in evaluating food policies and measuring diet-related disease burdens, the present scoping review serves as an exercise to inform future modelling, hereby highlighting the need for transparency in model development, application and dissemination to advance and safeguard accuracy and relevance in modelling efforts.Entities:
Keywords: Food policies; chronic diseases; health decision-making; microsimulation modelling; public health
Year: 2021 PMID: 34694330 PMCID: PMC8970827 DOI: 10.1093/advances/nmab129
Source DB: PubMed Journal: Adv Nutr ISSN: 2161-8313 Impact factor: 8.701
FIGURE 1Flowchart of the literature review (PRISMA flow diagram). Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Chronological overview of the use of microsimulation models in assessing the impact of diet and food policies in relation to NCD burden
| Author, year, reference | Countries | Food policy scenarios | NCDs of interest | Outcome measure of main analysis |
|---|---|---|---|---|
| Bertram et al., 2010 ( | AU | Lifestyle intervention (diet and exercise) after T2DM screening | T2DM, CHD, stroke, ESRD | CEA; i.e., costs/DALY |
| Basu et al., 2013 ( | IN | Tax (palm oil) | MI ischemic stroke | CVD deaths |
| Basu et al., 2013 ( | US | Tax (SSBs) and subsidies (F&V) through SNAP | T2DM, MI, stroke | CEA; i.e., costs/QALYs |
| Basu et al., 2014 ( | US | Tax (SSBs) and subsidies (F&V) through SNAP | Overweight/obesity, T2DM | Obesity prevalence, T2DM incidence |
| Basu et al., 2014 ( | US | Tax (SSBs) | Overweight/obesity, T2DM | Overweight/obesity prevalence |
| Dall et al., 2015 ( | US | Diabetes Prevention Program based on a lifestyle (diet and exercise) intervention | Overweight/obesity, T2DM, CVD events | Medical expenditures |
| Gortmaker et al., 2015 ( | US | Obesity reduction policy[ | Childhood obesity | CEA; i.e., costs/BMI unit reduction |
| Choi et al., 2016 ( | US | National Salt Reduction Initiative | Hypertension MI, Stroke | CVD incidence and mortality |
| Kypridemos et al., 2016 ( | UK | Population-wide combinations of dietary interventions[ | CHD, stroke | Cases/deaths prevented/postponed SII[ |
| Breeze et al., 2017 ( | UK | Tax (SSBs), retail policy (F&V), worksite healthy eating promotion, community education programs | T2DM and related complications/disorders | CEA; i.e., costs/QALY |
| Choi et al., 2017 ( | US | Subsidies (F&V) through SNAP | Obesity, T2DM, MI, stroke | CEA; i.e., costs/QALY |
| Kypridemos et al., 2017 ( | UK | Salt reduction policy through reformulation, taxes, public awareness campaigns, food labeling | CHD, stroke, GCa | Cases/deaths prevented/postponed SII[ |
| Pitt and Bendavid, 2017 ( | US | Price change of meat and seafood | Obesity | Obesity prevalence, QALY |
| Vreman et al., 2017 ( | US | Added sugar reduction policy (unspecified) | NAFLD, overweight, T2DM, CHD | Population disease prevalence DALYs, direct medical costs |
| Basu et al., 2018 ( | SY, JO, LB, GZ | Food aid delivery | T2DM, MI, stroke | Population disease incidence CEA; i.e., costs/DALYs |
| Javanbakht et al., 2018 ( | IR | Optimal intake of dairy | T2DM, CHD, stroke | Avoidable T2DM/CVD health-care costs |
| Mozaffarian et al., 2018 ( | US | Tax (SSBs) and subsidies (F&V) through SNAP | T2DM, CHD, stroke | Cases/deaths prevented/postponed CEA; i.e., costs/QALYs |
| Pearson-Stuttard et al., 2018 ( | US | Salt reduction policy through reformulation | CHD, stroke | Cases/deaths prevented/postponed CEA; i.e., costs/QALYs |
| Collins et al., 2019 ( | US | Salt reduction policy through reformulation | CHD, stroke | Cases/deaths prevented/postponed CEA; i.e., costs/QALYs |
| Grummon et al., 2019 ( | US | Health warning policy (SSB) | Obesity | Obesity prevalence |
| Huang et al., 2019 ( | US | Added sugar reduction policy through labeling and reformulation | T2DM, CHD, stroke | T2DM/CVD deaths prevented CEA; i.e., costs/QALYs |
| Jardim et al., 2019 ( | US | Optimal intake of 10 dietary factors | T2DM, MI, angina, stroke | Annual T2DM/CVD costs related to suboptimal intake |
| Laverty et al., 2019 ( | UK | Salt reduction policy through reformulation | CVD, GCa | CVD/GCa deaths, health costs, equity impacts |
| Lee et al., 2019 ( | US | Subsidy (Healthy foods) | T2DM, CHD, stroke | CVD/T2DM cases prevented CEA; i.e., costs/QALY |
| Long et al., 2019 ( | US | Tax (SSB) through SNAP | (Childhood) obesity | CEA; i.e., costs/QALY |
| Wilde et al., 2019 ( | US | Tax (SSBs) | CHD, stroke | CVD cases prevented/postponed CEA; i.e., costs/QALY |
| Basu et al., 2020 ( | US | Sales ban (SSBs) | Overweight/obesity, T2DM, CHD, stroke, chronic kidney disease | CEA; i.e., costs/QALY |
| Basu et al., 2020 ( | US | Purchases of farm's produce through Community-Supported Agriculture | T2DM, MI, stroke | CEA; i.e., costs/DALY |
| Broeks et al., 2020 ( | NL | Tax (meat) and subsidies (F&V) | T2DM, stroke, CHD, lung, colorectal cancer | CEA; i.e., costs/QALY |
| Dehmer et al., 2020 ( | US | Salt reduction policy through reformulation | Hypertension, MI, stroke | Averted medical costs by payer productivity gains |
| Lee et al., 2020 ( | US | Tax (SSBs and sugar content) | T2DM, CHD, stroke | CEA; i.e., costs/QALY |
| Liu et al., 2020 ( | US | Menu calorie labeling | T2DM, CHD, stroke | CEA; i.e., costs/QALY |
| Choi et al., 2021 ( | US | SSB purchase restrictions in SNAP | Childhood obesity | Obesity prevalence |
Abbreviations: AU, Australia; CEA, cost-effectiveness analysis; CHD, coronary heart disease; CVD, cardiovascular disease; DALY, disability-adjusted life-years; ESRD, end-stage renal disease; F&V, fruits and vegetables; GCa, gastric cancer; GZ, Gaza Strip; IN, India; IR, Ireland; JO, Jordan; LB, Lebanon; MI, myocardial infarction; NAFLD, nonalcoholic fatty liver disease; NCD, noncommunicable disease; NL, the Netherlands; QALY, quality-adjusted life-years; SII, Slope Index of Inequality; SNAP, Supplemental Nutrition Assistance Program; SSB, sugar-sweetened beverages; SY, Syria; T2DM, type 2 diabetes mellitus; UK, United Kingdom; US, United States
Obesity reduction policies include SSBs excise taxes, elimination of the tax subsidy for advertising unhealthy food, restaurant menu calorie labeling, nutrition standards for school meals, nutrition standards for foods/beverages sold in schools, improved early care and education, and increased access to adolescent bariatric surgery.
Population-wide dietary interventions include an SSB tax, salt policies, and F&V subsidies combined with taxing unhealthy foods. Their impacts on NCDs were modeled together and additionally included the impact of a smoking cessation intervention.
SII included absolute inequity: that is, the impact of an intervention expressed in the amount of cases in the most deprived areas compared with the least deprived areas (magnitude of the difference), and the relative inequity accounts for a preexisting socio-economic gradient of disease burden, showing proportional differences.
Microsimulation models for diet, food policies, and NCDs, and their modeling approaches for formulating the starting cohort and estimating individual disease risks
| Approaches | Short explanation | References | |
|---|---|---|---|
| Model type | Dynamic,discrete-time,stochasticmicrosimulationmodel | For each individual in the population, a set of randomly treated transition rules, determined by individual characteristics, are applied at each time step, leading to the possibility of transitioning to another health state (that are mutually exclusivecompeting and exhaustive) or death. | CVD PREDICT ( |
| US IMPACT Food Policy Model ( | |||
| CHOICES model ( | |||
| IMPACTNCD model ( | |||
| SPHR Diabetes Prevention Model ( | |||
| ModelHealth CVD ( | |||
| Unspecified ( | |||
| Partial micro-simulation | Markov-type state-transition model that combines microsimulation of risk factors with macrosimulation of disease and survival | DYNAMO-HIA model ( | |
| Disease Prevention Microsimulation Model ( | |||
| Unspecified ( | |||
| Formulation of the starting cohort | Weighted sampling (with replacements) | Expansion of the survey sample by sampling individuals from the survey with replacements using sample weights; only possible if the survey reports all baseline variables needed | ( |
| Generating a “close-to-reality” synthetic population | Expansion of the survey sample with other data sources, using statistical approaches such as synthetic reconstruction, model-based generations, combinatorial optimization, and/or (non-)parametric statistical matching | ( | |
| Simulating an individual by sampling from cohort-specific joint probability distributions; guided by correlation matrix of risk factors | ( | ||
| Estimation of individual disease risk | From literature and/or published incidence/prevalence rates | Using multi-state life tables with 1-year intervals to estimate disease probability | ( |
| Hazard calculation approach | Calculating an individual's relative hazard of an event in relation to the typical hazard in the cohort that year, and multiplying this ratio by the cohort- and year-specific incidence rate to estimate his/her disease probability | ( | |
| Risk score framework | Using risk functions with the specific risk exposures of an individual to estimate his/her disease probability | Framingham risk equations ( | |
| Comparative Risk Assessment framework | Using population-attributable fractions to estimate disease incidence not attributable to modeled risk factors, and multiplying this not-attributable incidence by the relative risks of specific risk exposures of an individual to estimate his/her disease probability. | ( |
ModelHealth CVD is a stochastic discrete-time model to estimate life-time incidence of CVD events and associated costs in a representative cross-section of US population. Abbreviations: CHOICES model, Childhood Obesity Interventions Cost-Effectiveness Study project; CVD, cardiovascular disease; CVD PREDICT model, Cardiovascular Disease Policy Model for Risk, Events, Detection, Interventions, Costs and Trends; DYNAMO-HIA model, Dynamic Modelling for Health Impact Analysis; NCD, noncommunicable disease; QRISK2, a cardiovascular disease risk algorithm version 2; RECODe, Risk Equations for Complications Of type 2 Diabetes; SPHR, School for Public Health Research Diabetes Prevention Model.
Model assessment, including model validity, scenario sensitivity and uncertainty analyses
| Model assessment | Examples on how this is carried out | |
|---|---|---|
| Model validation | Face validity | Manually checking each transition ( |
| Manually checking sampling values ( | ||
| Internal validation | Model calibration to national data ( | |
| Comparison of the synthetic population with the original sample of the Health Survey of England to internally validate the synthetic population and their risk factor trends ( | ||
| Baseline hazard rate in the risk equations of disease incidence and mortality calibrated to observed rates in health audits ( | ||
| Annual case fatality for CVD calibrated to forecasted mortality rates in a population attributable risk framework ( | ||
| External validation | Comparison against | |
| Historical/observed data ( | ||
| Forecasted/predicted data ( | ||
| Scenario sensitivity analysis | Modeling results under variousscenarios in 1-way sensitivityanalyses | Varying values of model parameters: |
| Tax/subsidy/funding/sales ban levels ( | ||
| Consumption trends, including purchases trends ( | ||
| Diet-risk factor associations ( | ||
| Options in intervention strategy ( | ||
| Participation rate ( | ||
| Participation time length/intervention duration ( | ||
| Intervention efficacy during and afterwards ( | ||
| Discount rate and willingness to pay ( | ||
| Policy size effects of labeling and food reformulation ( | ||
| Elasticities ( | ||
| Bias in dietary recall ( | ||
| Additional disease outcome: | ||
| Lung cancer ( | ||
| Uncertainty analysis | Parameter uncertainty analyses(second-order) | Deterministic sensitivity analysis ( |
| Probabilistic sensitivity analysis | ||
|
| ||
| 100 times in ( | ||
| 1000 times in ( | ||
| 10,000 times in ( | ||
| Not specified in ( | ||
|
| ||
| 1000 times in ( | ||
| 2000 times in ( | ||
| Copula functions ( | ||
Abbreviation: CVD, cardiovascular disease.
| Definition | References | |
| Individual-level state-transition models | For each individual, his/her disease history is simulated by applying a set of randomly treated transition processes that operate in discrete time intervals, often annually. | ( |
| Base-case scenario | A natural disease history model that describes the course of the disease process from onset to progression to death in a biologically meaningful and representative way whilst being mathematically as simple as possible and using estimable model parameters. | ( |
| Food policy scenario | A counterfactual scenario that can potentially modify an individual's diet and alter the natural disease history. | ( |
| Starting cohort | A theoretical group of individuals defined by a set of demographic and clinical characteristics relevant for the course of the disease process modeled. In an individual-level state-transition model, cohort members might be heterogenous in their demographic and clinical characteristics. Often the cohort is a synthetic population—i.e., the characteristics of the population match the various statistical distributions of the real population—and is therefore a close-to-reality population to be used in modeling. | ( |
| States | Relevant states in a simple state-transition model include: “health,” “disease,” and “death,” with disease being an intermediate state between health and death, and death being an absorbing state. States are collectively exhaustive and mutually exclusive: i.e., an individual can only be in exactly 1 state at each model cycle. Further specifications of distinct states, including the number of distinct states, depend on the disease process, the research question, and data availability, as well as how demographic and clinical characteristics are attributed to states. | ( |
| Transition probabilities | Individuals are allowed to move between states, with their probabilities of moving depending on demographic and clinical characteristics and the current state, and possibly also accounting for previous states’ histories. | |
| Time horizon | The follow-up time of the cohort, related to the number of cycles. | |
| Cycle length | The time period between the potential transitions to distinct health states, and the duration of experiencing particular events. | |
| Validation analyses | A kind of model assessment that refers to the consistency of the model with observed/predicted data. Validation for decision modeling includes face validity (plausibility), internal validity (verification), cross validity (between-model comparison, external consistency), external historical validity, and external predictive validity. | ( |
| Scenario sensitivity analyses | A kind of model assessment that refers to the explorations of model results under various scenarios, often varying model parameters that are inestimable or poorly estimable. | ( |
| Uncertainty analyses | A kind of model assessment that refers to the variability/uncertainty inherent to the modeling, aimed at better informing the decision by assessing confidence in a chosen modeling strategy and/or determining the need for additional information. Uncertainty for decision modeling includes stochastic uncertainty, parameter uncertainty, heterogeneity, and structural uncertainty. | ( |